Free Trial
ASX:TLX

Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Telix Pharmaceuticals logo

About Telix Pharmaceuticals Stock (ASX:TLX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
746,789 shs
Average Volume
N/A
Market Capitalization
$9.14 billion
P/E Ratio
290.42
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TLX Stock News Headlines

Telix at ANZSNM Annual Scientific Meeting 2025
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Telix Pharmaceuticals Ltd ADR (TLX)
See More Headlines

TLX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Telix Pharmaceuticals investors own include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Esperion Therapeutics (ESPR), Forte Biosciences (FBRX), Faraday Future Intelligent Electric (FFIE), Abbott Laboratories (ABT) and ADMA Biologics (ADMA).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:TLX
CIK
N/A
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

Trailing P/E Ratio
290.42
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$49.19 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$645.68 million
Price / Cash Flow
8.35
Book Value
A$1.21 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$9.14 billion
Optionable
Not Optionable
Beta
2.40
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:TLX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners